Genomics and proteomics in venous thromboembolism: building a bridge toward a rational personalized medicine framework.
Venous thromboembolism is a major health care problem worldwide and is sustained by a multifactorial pathogenesis where both congenital and acquired causes contribute. It is increasingly being highlighted that a reliable approach based on genomics and proteomics might be effective to construct a rational personalized medicine framework that can be applied in the preclinical, clinical, and therapeutic settings of venous thrombosis. The aim of this review is to provide a concise description of the current and future applications of genomics and proteomics in this challenging pathology.
Lippi
Giuseppe
G
Sezione di Chimica Clinica, Dipartimento di Scienze Biomediche e Morfologiche, Università di Verona, Verona, Italy. giuseppe.lippi@univr.it
Franchini
Massimo
M
Montagnana
Martina
M
Guidi
Gian Cesare
GC
D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use; D023281:Genomics / Q000379:methods*; D006801:Humans; D010597:Pharmacogenetics; D040901:Proteomics / Q000379:methods*; D019851:Thrombophilia / Q000097:blood / Q000235:genetics*; D054556:Venous Thromboembolism / Q000097:blood / Q000235:genetics / Q000378:metabolism / Q000628:therapy; D014859:Warfarin / Q000008:administration & dosage / Q000627:therapeutic use
D000925:Anticoagulants; D014859:Warfarin